-
EP2832856
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2832856
| EP2832856 - ANTI-LAMP5 ANTIBODY AND UTILIZATION THEREOF [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 14.12.2018 Database last updated on 14.05.2024 | |
| Former | Grant of patent is intended Status updated on 13.03.2018 | ||
| Former | Examination is in progress Status updated on 27.01.2017 | Most recent event Tooltip | 14.12.2018 | Application deemed to be withdrawn | published on 16.01.2019 [2019/03] | Applicant(s) | For all designated states Chugai Seiyaku Kabushiki Kaisha 5-1, Ukima 5-chome Kita-ku Tokyo 115-8543 / JP | [2015/06] | Inventor(s) | 01 /
KAWAI Shigeto c/o Forerunner Pharma Research Co. Ltd. 2-16 Komaba 4-chome Meguro-ku Tokyo 153-0041 / JP | [2015/06] | Representative(s) | J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | [N/P] |
| Former [2015/06] | Campbell, Patrick John Henry J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB | Application number, filing date | 13767407.3 | 29.03.2013 | WO2013JP59516 | Priority number, date | JP20120076735 | 29.03.2012 Original published format: JP 2012076735 | [2015/06] | Filing language | JA | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2013147153 | Date: | 03.10.2013 | Language: | JA | [2013/40] | Type: | A1 Application with search report | No.: | EP2832856 | Date: | 04.02.2015 | Language: | EN | [2015/06] | Search report(s) | International search report - published on: | JP | 03.10.2013 | (Supplementary) European search report - dispatched on: | EP | 07.01.2016 | Classification | IPC: | C12N15/09, A61K39/395, A61P35/00, C07K19/00, C12N1/15, C12N1/19, C12N1/21, C12N5/10, C12P21/08, C07K14/54, A61K38/20, C07K14/705, C07K16/28 | [2018/13] | CPC: |
C07K16/2896 (EP,US);
C07K16/28 (US);
A61K38/204 (EP,US);
A61K39/3955 (US);
A61K47/6849 (EP,US);
A61K47/6851 (US);
A61P35/00 (EP);
C07K14/5412 (EP,US);
C07K14/70596 (EP,US);
C07K2317/56 (EP,US);
C07K2317/565 (EP,US);
C07K2317/732 (EP,US);
C07K2317/76 (US);
C07K2317/77 (US);
C07K2319/00 (EP,US);
C07K2319/42 (EP,US)
(-)
|
| Former IPC [2015/45] | C12N15/09, A61K39/395, A61P35/00, C07K19/00, C12N1/15, C12N1/19, C12N1/21, C12N5/10, C12P21/08, C07K14/54, A61K38/20, A61K47/48, C07K14/705, C07K16/28 | ||
| Former IPC [2015/06] | C12N15/09, A61K39/395, A61P35/00, C07K19/00, C12N1/15, C12N1/19, C12N1/21, C12N5/10, C12P21/08 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2015/06] | Title | German: | ANTI-LAMP5-ANTIKÖRPER UND VERWENDUNG DAVON | [2015/06] | English: | ANTI-LAMP5 ANTIBODY AND UTILIZATION THEREOF | [2015/06] | French: | ANTICORPS ANTI-LAMP5 ET SON UTILISATION | [2015/06] | Entry into regional phase | 28.10.2014 | Translation filed | 28.10.2014 | National basic fee paid | 28.10.2014 | Search fee paid | 28.10.2014 | Designation fee(s) paid | 28.10.2014 | Examination fee paid | Examination procedure | 28.10.2014 | Examination requested [2015/06] | 18.07.2016 | Amendment by applicant (claims and/or description) | 31.01.2017 | Despatch of a communication from the examining division (Time limit: M06) | 28.07.2017 | Reply to a communication from the examining division | 18.08.2017 | Despatch of a communication from the examining division (Time limit: M04) | 15.12.2017 | Reply to a communication from the examining division | 14.03.2018 | Communication of intention to grant the patent | 25.07.2018 | Application deemed to be withdrawn, date of legal effect [2019/03] | 30.08.2018 | Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2019/03] | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 31.01.2017 | Fees paid | Renewal fee | 25.03.2015 | Renewal fee patent year 03 | 10.03.2016 | Renewal fee patent year 04 | 10.03.2017 | Renewal fee patent year 05 | 23.03.2018 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XI]WO2005001092 (WYETH CORP [US], et al) [X] 1-5,10,11,13 * abstract * * paragraphs [0003] , [0006] , [0007] , [0010] , [0020] - [0022] - [0077] , [0120] , [0121] , [0187] - [0193] - [0200] * [I] 6-9,12,14,15; | [XI]EP1932854 (INST NAT SANTE RECH MED [FR]) [X] 5,11,12 * abstract * * paragraphs [0053] - [0055] * * examples 3, 4 * * figure 15 * [I] 13-15; | [XI]JP2008162954 (KIRIN PHARMA CO LTD) [X] 1-5,10-13,15 * abstract * * paragraphs [0001] , [0011] , [0012] - [0023] - [0030] , [0031] , [0037] - [0046] - [0051] * * examples 8, 10, 11 * [I] 6-9,14; | [XI] - AXEL DEFAYS ET AL, "BAD-LAMP is a novel biomarker of nonactivated human plasmacytoid dendritic cells", BLOOD, (20110101), vol. 118, doi:10.1182/blood-2010-, pages 609 - 617, XP055171209 [X] 5,11,12 * page 610 * [I] 13-15 DOI: http://dx.doi.org/10.1182/blood-2010-11-319699 | International search | [Y]JPH05506574 (THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK); | [X]EP1932854 (INST NAT SANTE RECH MED [FR]); | [Y]WO2010119691 (UNIV TOKYO [JP], et al); | [Y]WO2011093097 (FORERUNNER PHARMA RES CO LTD [JP], et al); | [X] - AXEL DEFAYS ET AL., "BAD-LAMP is a novel biomarker of nonactivated human plasmacytoid dendritic cells", BLOOD, (20110721), vol. 118, no. 3, pages 609 - 617, XP055171209 DOI: http://dx.doi.org/10.1182/blood-2010-11-319699 | by applicant | US4588585 | EP0239400 | US4737462 | US4879111 | US4904584 | US4959314 | US4965195 | US5017691 | WO9201047 | WO9203918 | US5116943 | WO9213095 | WO9220791 | WO9306213 | WO9311236 | WO9312227 | WO9319172 | WO9402602 | WO9403492 | WO9411523 | WO9425585 | WO9501438 | WO9515388 | WO9602576 | WO9634096 | WO9633735 | WO9732891 | WO9902552 | WO9954342 | EP0656117 | EP0667872 | EP0504751 | WO0042072 | WO0061739 | WO0103737 | WO0231140 | WO02079225 | WO2004029207 | WO2004065540 | WO2004099249 | WO2005070963 | WO2006020114 | WO2006023403 | WO2006031370 | WO2006067913 | WO2006105338 | WO2006116260 | WO2007021841 | WO2007024249 | WO2007041635 | WO2008081088 | WO2008092117 | WO2008093688 | - BAD-LAMP, "defines a subset of early endocytic organelles in subpopulations of cortical projection neurons", J. CELL SCI., (2007), vol. 120, pages 353 - 65 | - BAD-LAMP, "is a novel biomarker of nonactivated human plasmacytoid dendritic cells", BLOOD, (2011), vol. 118, doi:doi:10.1182/blood-2010-11-319699, pages 609 - 17, XP055171209 DOI: http://dx.doi.org/10.1182/blood-2010-11-319699 | - "The plasmacytoid monocyte/interferon producing cells", VIRCHOWS ARCH., (2003), vol. 443, pages 703 - 17 | - "Novel markers of normal and neoplastic human plasmacytoid dendritic cells", BLOOD, (2008), vol. 111, pages 3778 - 92 | - "Intracellular trafficking of lysosomal membrane proteins", BIOASSAYS, (1996), vol. 18, pages 379 - 89 | - "Lysosomal membrane glycoproteins: structure, biosynthesis and intracellular trafficking", J. BIOL. CHEM., (1991), vol. 266, pages 21327 - 30 | - "Expression of Lamp-1 and Lamp-2 and their interactions with galectin-3 in human tumor cells", INT. J. CANCER, (1998), vol. 75, pages 105 - 11 | - Epitope Mapping Protocols in Methods in Molecular Biology, (1996), vol. 66 | - Antibodies: A Laboratory Manual, COLD SPRING HARBOR LABORATORY, (1988), pages 359 - 420 | - SAMBROOK, J. ET AL., Molecular Cloning, COLD SPRING HARBOR LABORATORY PRESS, (1989), pages 9.47 - 9.58 | - J. IMMUNOL., (1979), vol. 123, no. 4, pages 1548 - 1550 | - CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY, (1978), vol. 81, pages 1 - 7 | - C. EUR. J. IMMUNOL., (1976), vol. 6, no. 7, pages 511 - 519 | - CELL, (1976), vol. 8, no. 3, pages 405 - 415 | - NATURE, (1978), vol. 276, no. 5685, pages 269 - 270 | - J. IMMUNOL. METHODS, (1980), vol. 35, no. 1-2, pages 1 - 21 | - J. EXP. MED., (1978), vol. 148, no. 1, pages 313 - 323 | - NATURE, (1979), vol. 277, no. 5692, pages 131 - 133 | - KOHLER; MILLSTEIN, METHODS ENZYMOL., (1981), vol. 73, pages 3 - 46 | - VANDAMME ET AL., EUR. J. BIOCHEM., (1990), vol. 192, no. 3, pages 767 - 775 | - BIOCHEMISTRY, (1979), vol. 18, no. 24, pages 5294 - 5299 | - ANAL. BIOCHEM., (1987), vol. 162, no. 1, pages 156 - 159 | - PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, no. 23, pages 8998 - 9002 | - NUCLEIC ACIDS RES., (1989), vol. 17, no. 8, pages 2919 - 2932 | - BIO/TECHNOLOGY, (1994), vol. 12, no. 7, pages 699 - 702 | - CANCER RES., (1993), vol. 53, pages 851 - 856 | - BERNASCONI ET AL., SCIENCE, (2002), vol. 298, pages 2199 - 2202 | - KUNKEL ET AL., PROC. NATL. ACAD. SCI. USA, (1985), vol. 82, pages 488 - 492 | - ANNU. REV. BIOPHYS. BIOMOL. STRUCT., (2006), vol. 35, pages 225 - 249 | - PROC. NATL. ACAD. SCI. USA, (2003), vol. 100, no. 11, pages 6353 - 6357 | - J. BIOL. CHEM., (2003), vol. 278, pages 3466 - 3473 | - J. PHARM. SCI., (1994), vol. 83, no. 12, pages 1670 - 1675 | - J. CLIN. INVEST., (2001), vol. 108, no. 11, pages 1687 - 95 | - ANAL. BIOCHEM., (1995), vol. 230, no. 2, pages 229 - 238 | - LANGONE, J. J. ET AL., METHODS IN ENZYMOLOGY, (1983), vol. 93, pages 307 - 308 | - NATURE MEDICINE, (1996), vol. 2, pages 350 - 353 | - FULTON, R.J. ET AL., J. BIOL. CHEM., (1986), vol. 261, pages 5314 - 5319 | - SIVAM, G. ET AL., CANCER RES., (1987), vol. 47, pages 3169 - 3173 | - CUMBER A. J. ET AL., J. IMMUNOL. METHODS, (1990), vol. 135, pages 15 - 24 | - WAWRZYNCZAK E. J. ET AL., CANCER RES., (1990), vol. 50, pages 7519 - 7562 | - GHEEITE V. ET AL., J. IMMUNOL. METHODS, (1991), vol. 142, pages 223 - 230 | - THORPE, P.E. ET AL., CANCER RES., (1987), vol. 47, pages 5924 - 5931 | - WAWRZYNCZAK E. J. ET AL., BR. J. CANCER, (1992), vol. 66, pages 361 - 366 | - SIVAM G. ET AL., CANCER RES, (1987), vol. 47, pages 3169 - 3173 | - CUMBER, A. J. ET AL., J. IMMUNOL. METHODS, (1990), vol. 135, pages 15 - 24 | - BOLOGNESI, A. ET AL., CLIN. EXP. IMMUNOL., (1992), vol. 89, pages 341 - 346 | - STIRPE, F.; BARBIERI, L., FEBS LETTERS, (1986), vol. 195, pages 1 - 8 | - CASELLAS, P. ET AL., EUR. J. BIOCHEM., (1988), vol. 176, pages 581 - 588 | - CORBI ET AL., EUR. J. CARDIOTHERAC. SURG., (2000), vol. 18, no. 1, pages 98 - 103 | - KADO ET AL., ACTA DIABETOL., (1999), pages 67 - 72 | - CHEBATH ET AL., EUR. CYTOKINE NETW., (1997), pages 359 - 365 | - KOLLET ET AL., BLOOD, (1999), vol. 94, no. 3, pages 923 - 31 | - AUSUBEL ET AL., Current Protocols in Molecular Biology, Supra, INTERSCIENCE, (1987), pages 6.3 - 6.4 | - "Initial genome sequencing and analysis of multiple myeloma", NATURE, (2011), vol. 471, pages 467 - 72 | - "Enforced and prolonged CD40 ligand expression triggers antibody production in vivo", EUR. J. IMMUNOL., (2001), vol. 31, pages 3484 - 92 | - "Synergistic antibody induction by antigen - CD40 ligand fusion protein as improved immunogen", IMMUNOLOGY, (2005), vol. 115, pages 215 - 22 |